Rett syndrome

Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference

Retrieved on: 
Monday, March 25, 2024
Therapy, Central nervous system, CNS, Rett syndrome, Conference, Schizophrenia, DSM-IV codes, Doctor of Philosophy

NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024.

Key Points: 
  • NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 23rd Annual Needham Virtual Healthcare Conference, April 8 – 11, 2024.
  • Christopher U Missling, PhD, President & Chief Executive Officer will present the Company scheduled at 8:45 AM (ET) on Monday, April 8th, 2024.
  • A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com .
  • An archived edition of the session will be available later that day.

AVXL INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Anavex Life Sciences Corporation Investors with Substantial Losses Have Opportunity to Lead Case

Retrieved on: 
Monday, March 25, 2024
Central nervous system, Patient, SAN, News, Rett, Rett syndrome, Complaint, Excellence, Tobacco

), the Anavex class action lawsuit charges Anavex as well as Anavex executives with violations of the Securities Exchange Act of 1934.

Key Points: 
  • ), the Anavex class action lawsuit charges Anavex as well as Anavex executives with violations of the Securities Exchange Act of 1934.
  • Lead plaintiff motions for the Anavex class action lawsuit must be filed with the court no later than May 13, 2024.
  • A lead plaintiff acts on behalf of all other class members in directing the Anavex class action lawsuit.
  • An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Anavex class action lawsuit.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, Anavex, and Innoviz and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, March 23, 2024
Bitcoin, Research, Bankruptcy, Patient, Defendant, News, Data mining, Rett syndrome, Complaint, Hut 8, P.C, Clinical trial, MCI, Radar, Mergers and acquisitions, Cryptocurrency

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Additional information about each case can be found at the link provided.
  • In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).
  • For more information on the Innoviz class action go to: https://bespc.com/cases/INVZ

AVXL Class Action Notice: Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Anavex Life Sciences Corporation Class Action

Retrieved on: 
Thursday, March 21, 2024
Rett, Excellence, Central nervous system, Patient, SAN, CNS, Rett syndrome, Complaint, News, LLP, Person, Pharmaceutical industry

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.

Key Points: 
  • SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons who purchased or otherwise acquired Anavex Life Sciences Corporation (NASDAQ: AVXL) stock between February 1, 2022 and January 1,2024.
  • What Now: You may be eligible to participate in the class action against Anavex Life Sciences Corporation.
  • Shareholders who want to serve as lead plaintiff for the class must file their papers with the court by May 13, 2024.
  • A lead plaintiff is a representative party who acts on behalf of other class members in directing the litigation.

Levi & Korsinsky Notifies Shareholders of Anavex Life Sciences Corporation(AVXL) of a Class Action Lawsuit and an Upcoming Deadline

Retrieved on: 
Thursday, March 21, 2024
Telephone, Patient, News, LLP, CLASS, Rett syndrome, Clinical trial, MCI, Radar, NEXT, COST, Court, Cryptocurrency

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Anavex Life Sciences Corporation ("Anavex Life Sciences" or the "Company") (NASDAQ: AVXL) of a class action securities lawsuit.
  • CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Anavex Life Sciences investors who were adversely affected by alleged securities fraud between February 1, 2022 and January 1, 2024.
  • Follow the link below to get more information and be contacted by a member of our team:
    AVXL investors may also contact Joseph E. Levi, Esq.
  • For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.

AVXL INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Anavex Life Sciences Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Retrieved on: 
Thursday, March 21, 2024
Central nervous system, Patient, CNS, Research, Neurodevelopmental disorder, News, Avatar, Rett syndrome, Complaint, Fraud, Excellence, FDA, Central nervous system disease, Court, Person, Pharmaceutical industry

Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.

Key Points: 
  • Anavex has sponsored several research studies concerning blarcamesine’s suitability to treat various CNS disorders.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660.
  • If you suffered a loss in Anavex you have until May 13, 2024, to request that the Court appoint you as lead plaintiff.
  • Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits.

Shareholders of Anavex Life Sciences Corporation Should Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights – AVXL

Retrieved on: 
Wednesday, March 20, 2024
Patient, News, Rett syndrome, Clinical trial, MCI, Fraud, Radar, NEXT, Security (finance)

NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation.

Key Points: 
  • NEW YORK, March 20, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Anavex Life Sciences Corporation.
  • Shareholders who purchased shares of AVXL during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment.
  • ANAVEX®2-73 met the primary endpoints ADAS-Cog1 and ADCS-ADL2 and key secondary endpoint CDR-SB3 with statistically significant results.
  • The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Taysha Gene Therapies Reports Full Year 2023 Financial Results and Provides Corporate and Clinical Updates

Retrieved on: 
Tuesday, March 19, 2024
Diary, Patient, IND, Adolescence, Pediatrics, Therapy, FAAP, Rett syndrome, Research, Central nervous system, Risk, Webcast, CNS, Ageing, CHU, Safety, AAV, Mutation, Development, MECP2, Disease, Associate, Sleep, Șaeș, Dysrhythmia, FRCP, MTD, Movement, IDMC, VG, Hyperventilation, Principal, Administration, Index, Seizure, CTA, Female, MHRA, Phenotype, ID, Frasier, Pharmaceutical industry

Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.

Key Points: 
  • Notably, she has vastly increased interest in social communication and activities at week 35 compared to earlier post-treatment assessments.
  • Dr. Schultz is a board-certified, licensed pediatric neurologist experienced in treating patients with Rett syndrome and leading gene therapy clinical trials.
  • She brings more than 17 years of clinical experience and will lead the Company’s clinical development, clinical operations, medical affairs and safety activities.
  • ET to review its financial and operating results and to provide corporate and clinical updates.

DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome

Retrieved on: 
Tuesday, March 19, 2024
PTP, Obesity, Enzyme, DSM-IV codes, Patient, Cancer, IND, Clinical trial, Safety, Family, Rett syndrome, Food, Pharmaceutical industry

Today, DepYmed announces it has received clearance from the U.S. Food and Drug Administration to initiate its phase 1 clinical trial for DPM-1003 for the treatment of Rett Syndrome.

Key Points: 
  • Today, DepYmed announces it has received clearance from the U.S. Food and Drug Administration to initiate its phase 1 clinical trial for DPM-1003 for the treatment of Rett Syndrome.
  • “This is a foundational achievement for DepYmed.
  • This includes Rett Syndrome, cancer, metabolic disease and obesity, and Alzheimer’s Disease.
  • We look forward to beginning to assess the safety and tolerability of DPM-1003 and continue our development of this compound for Rett Syndrome and our other ongoing programs.”

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hut 8, and Anavex and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, March 19, 2024
Bitcoin, Research, Bankruptcy, Patient, Defendant, News, Data mining, Rett syndrome, Hut 8, P.C, Clinical trial, MCI, Radar, Mergers and acquisitions, Cryptocurrency

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • Additional information about each case can be found at the link provided.
  • In November 2023, Hut 8 formed following the merger of Hut 8 Mining Corp. (“Legacy Hut”) and U.S. Data Mining Group, Inc. d/b/a US Bitcoin Corp. (“USBTC”) (the “Merger”).
  • For more information on the Anavex class action go to: https://bespc.com/cases/AVXL